Alveolar soft part sarcoma of the superior rectus muscle: Case report and review of literature

Seyed Mohsen Rafizadeh, Kasra Cheraqpour, Fahimeh Asadi Amoli, Ali A. Haydar

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
Ophthalmic Pathology Department, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran

ARTICLE INFO
Keywords:
Alveolar soft part sarcoma
Orbit
Imaging
Histopathology
Immunohistochemistry
Exenteration

ABSTRACT
Purpose: Alveolar soft part sarcoma (ASPS) is a very rare type of soft tissue sarcomas which usually occurs in the limbs and trunk.
Observations: A 25-year-old woman presented with proptosis and redness of the right eye for 8-month. She suffered from severe right upper lid edema, conjunctival chemosis, downward displacement of the globe, and proptosis. Radiological imaging was nonconclusive. Histopathological evaluations confirmed ASPS. The patient underwent exenteration as a lifesaving procedure. At 16-month follow-up, the patient is stable without any signs of recurrence or metastasis.
Conclusions and importance: We report an extremely rare case of ASPS occurring in the superior rectus muscle. Few orbital ASPS cases have been reported in the literature. A literature review of orbital ASPS was done to shed lights on the diagnosis and management of this rare tumor.

1. Introduction

Alveolar soft part sarcoma (ASPS) is a very rare type of soft tissue sarcomas that commonly occurs in the limbs and trunk of adults and head and neck of children. ASPS accounts for less than 1% of all sarcomas and is unusual to form primarily in the orbit. ASPS seems to affect more females and the left orbit. Radiological findings and typical histopathological features can establish the diagnosis. Currently, the management is mainly complete tumor resection. Herein, we report a case of superior rectus muscle ASPS in a young female, and we review the literature.

2. Case report

A 25-year-old female presented to our oculoplastic service at Farabi eye hospital with a painless proptosis and redness of the right eye for 8-month. Her initial best-corrected visual acuity (BCVA) was counting fingers at 2 m and 20/25 in the right and left eye, respectively. External examination of the right eye showed severe ptosis, severe proptosis, downward displacement of the globe, and limitation of movement in all gazes (Fig. 1A). Slit-lamp examination revealed severe eyelid erythema and edema, conjunctival injection, and chemosis (Fig. 1B). The examination of the left eye was normal.

Orbital computed tomography (CT) scan showed a large ovoid extracranial homogenous solid mass measuring 5.2 × 2.5 cm. The lesion was in the right upper orbital cavity within the superior rectus-levator complex, causing globe indentation and optic nerve compression (Fig. 1C and D). Brain and orbital magnetic resonance imaging (MRI) showed no extension to the cranial fossa or the sinuses (Fig. 1E and F). No signs of metastasis were evident in the systemic examination or imaging.

Biopsy demonstrated foci of alveolar pattern separated by fibrous stroma (Fig. 2A). Neoplastic infiltration composed of large polygonal cells with eosinophilic granular cytoplasm containing nuclei with prominent nucleoli arranged in solid sheets were seen (Fig. 2B and C). Numerous tumor cells cytoplasm contained Periodic acid-Schiff (PAS) positive diastase granules (Fig. 2D). The tumor was highly vascular, and mitotic figures and tumor necrosis were present. Perineural and lymphovascular invasion were noticed. Muscle markers (vimentin, desmin, and myoglobin) and non-muscle markers (S-100 and Ki67) were used for immunohistochemical (IHC) staining in our case. All markers were negative. The histopathological and immunoprofile confirmed the diagnosis of ASPS. According to the eighth edition of the American Joint Committee for Cancer Classification (AJCC), the cancer had a T3M0N0 staging at the time of diagnosis.
The patient underwent concurrent neoadjuvant chemotherapy (Doxorubicin 20 mg/m² weekly for 8 cycles) and external beam radiotherapy (EBRT) with a total dose of 6000 cGY in 30 fractions over 5 weeks. Unfortunately, the response to the neoadjuvant treatment was poor and would be labeled stable disease as per the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. Therefore, orbital exenteration was inevitable. The resected tumor measured about 5.2 cm at its largest diameter. Based on our experience, we performed a minimal reconstruction and let the granulation tissues grow in the empty space. The cut surface of the tumor showed a homogeneous, yellowish appearance (Fig. 2E). The eye globe, optic nerve, and surgical margins were tumor free. Serial follow-up orbital MRIs were obtained and showed no evidence of recurrence or metastasis. At 16-month follow-up, the patient is still having complete response as per RECIST guidelines.

### 3. Discussion

ASPS is an extremely rare neoplasm of soft tissues and affects mainly children and young adults. More than 15% of ASPS cases involve the orbit. The high rate of relapse makes its early and correct diagnosis very crucial. These tumors grow slowly without pain. We reviewed the literature in PUBMED and found only 89 cases of orbital ASPS reported worldwide from 1963 till 2021. Table 1 summarizes the recent orbital ASPS cases reported in the literature. Our case is the second from the Middle East and North Africa region and first from Iran. The average age at diagnosis is 16.05 years with a median of 12 years (range 10 months–69 years). Children less than 20 years old made up 71.25% of the cases, and 41.25% were less than 10 years. There is a slight female predilection with a female-to-male ratio of 1.32:1 and a preferential involvement of the left orbit (57.75%). The average tumor size is 3.33 cm with a median of 3 cm (range 1.5–8.6 cm). Out of the 73 patients with follow-up data, 53 (72.60%) were alive with no evidence of disease and survival.

Using the Kaplan-Meier method, the calculated 1- and 11-year overall survival rates of reported orbital ASPS cases are 94.2% and 82.4%, respectively. Subgroup analysis for age and sex were not significant due to small sample size. Previously, Liberman et al. reported the 2- and 10-year survival rates of all ASPS to be 77% and 38%, respectively. Therefore, the orbital ASPS subtype might have a better long-term survival. The average follow-up duration was 46.54 months with a median of 16 months (range 1 month–248 months). Out of the 73 patients with follow-up data, 53 (72.60%) were alive with no evidence of disease and survival.

### Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| ASPS         | alveolar soft part sarcoma |
| BCVA         | best-corrected visual acuity |
| CT           | computed tomography |
| MRI          | magnetic resonance imaging |
| PAS          | periodic acid-Schiff |
| IHC          | immunohistochemical |
| AJCC         | American Joint Committee for Cancer Classification |
| EBRT         | external beam radiotherapy |
| RECIST       | Response Evaluation Criteria in Solid Tumors |
8 (10.96%) were alive with local recurrence. Six (8.22%) patients had lung metastasis, with one of these patients also exhibited brain metastasis and another liver metastasis. Six (8.22%) patients died due to ASPS recurrence or metastasis, and 3 (4.11%) patients died due to unrelated causes. A total of 9 patients were lost to follow-up.

The most common reported clinical findings are exophthalmos (81%), eyelid swelling (30%), and conjunctival congestion (20%). Pain, diplopia, and tearing are less frequent complaints. Decreased vision can be expected in case of optic nerve compression. Font et al. reported the median duration of symptoms to be 4 months (range 2–7 years). The symptoms are detected earlier in orbital ASPS cases—leading to a shorter disease course and smaller tumor size in comparison to non-orbital cases. The median age at diagnosis of 9 patients was 51 years (range 11–71 years). The symptoms are detected earlier in orbital ASPS cases—leading to a shorter disease course and smaller tumor size in comparison to non-orbital cases.
non-orbital cases is above 30 years.\textsuperscript{1} Orbital involvement can be primary or secondary due to invasion from paranasal sinuses.\textsuperscript{9}

It is postulated that the determining prognostic factors of ASPS are the presence of metastasis at diagnosis, large tumor size, and older age.\textsuperscript{11,12} Our patient was 25-year-old with large tumor size of 5.2 cm but no evidence of metastasis. The surgical margins were tumor free, and currently the patient exhibits no sign of recurrence 16-month postop. She was previously healthy. She underwent orbital exenteration, which is currently the best life-saving option.\textsuperscript{7,13,14} The survival rate of young patients less than 20 years is remarkably higher. Local recurrence may occur in 1/5 to 1/2 of orbital ASPS. Furthermore, metastasis is not uncommon even in late course.\textsuperscript{7} Hence, long-term follow-up is recommended.

Several differential diagnoses should be considered including rhabdomyosarcoma, hemangioma, melanoma, hibernoma, granular cell tumor, and metastasis.\textsuperscript{15} Histopathology, IHC, and genetic tests are sensitive techniques for diagnosis, whereas imaging shows unspecific findings. CT scan usually reveals a homogeneous, well-defined, iso-intense soft-tissue mass that enhances with contrast. MRI shows hyperintense signal intensity on T1 and T2-weighted images, and intense enhancement with contrast. ASPS can be highly vascular, which exhibits flow voids on MRA.\textsuperscript{16} Previous reports suggested that ASPS is of myogenic origin.\textsuperscript{9} In addition to our patient, we counted 29 patients from the literature whose tumors had been associated with extracocular muscles. Histologically, ASPS demonstrates round to polygonal tumor cells arranged in alveolar pattern and separated by fibrous septa. The abundant eosinophilic cytoplasm shows PAS-positive diastase-resistant granules in 80% of patients.\textsuperscript{17} ICH markers also help in the differential diagnosis. Positive nuclear staining of TFE3 is reported in up to 90% of ASPS cases.\textsuperscript{10} As seen in our patient, the Ki67 proliferative index is generally low indicating a slow growing tumor. Other ICH markers are usually negative or nonspecific.

The choice of surgical plan is controversial. Complete surgical removal of small tumors and saving the globe is ideal. Although recurrence is seldom if the tumor has been completely resected, adhesion to other structures such as extraocular muscles and achievement of free margins are challenging. Many cases of orbital ASPS require extirpation or aggressive surgical resection. Exenteration was done for 26.5% of the reported cases. ASPS has a resistant nature to chemotherapy and radiotherapy. Current chemo- and radiotherapy regimens do not improve the survival rate of ASPS. Though, adjuvant radiotherapy is associated with lower local recurrence rate.\textsuperscript{4,14} Resection of pulmonary metastasis is believed to prolong the survival rates of ASPS patients.\textsuperscript{5,46} Nevertheless, due to the young age of our patient and the large tumor size, a course of neoadjuvant chemoradiotherapy was done to achieve the most success rate. Our patient had poor response to doxorubicin, an anthracycline. Treatment with vincristine and cyclophosphamide have inconsistent results.\textsuperscript{17,46} Recent studies show ASPS sensitivity toward vascular endothelial growth factor receptor-tyrosine kinase inhibitors such as sunitinib, pazopanib, and cediranib.\textsuperscript{47} Preoperative embolization was suggested to facilitate a smooth tumor excision with minimal intraoperative bleeding.\textsuperscript{1,11}

4. Conclusions

In conclusion, orbital ASPS is a rare entity with no distinct clinical or radiological features. Histological and ICH are necessary for diagnosis. Neoadjuvant chemo- and radiotherapy are not effective. Total surgical resection is the current best option. Orbital ASPS has a better survival rate than ASPS in other locations. However, long-term follow-up is recommended due to potential recurrence. Future investigations are advised to delineate the best treatment protocol.

Patient consent

This report was prepared in accordance with the Declaration of Helsinki. The patient’s consent for the publication of identifiable photographs was also obtained.

Funding

No funding or grant support

Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Declaration of competing interest

None.

Acknowledgements

None.

References

1. Hei Y, Kang L, Yang X, et al. Orbital alveolar soft part sarcoma: a report of 8 cases and review of the literature. Oncol Lett. 2018;15(1):304–314.
2. Koka K, Singh P, Niar SP, et al. Role of pre-operative percutaneous embolization in orbital alveolar soft part sarcoma - an experience from a tertiary eye-care center. Indian J Ophthalmol. 2021;69(10):2796–2801.
3. Oda T, Kikuchi K, Togao O, et al. Alveolar soft part sarcoma of the orbit: a case report. Radiol Case Rep. 2021;16(12):3766–3771.
4. Huang SH, O’Sullivan B. Overview of the 8th edition TNM classification for head and neck cancer. Curr Treat Options Oncol. 2017;18(7):40.
5. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
6. Wang Y, Du B, Yang M, He W. Paediatric orbital alveolar soft part sarcoma recurrence during long-term follow-up: a report of 3 cases and a review of the literature. BMC Ophthalmol. 2020;20(1):50.
7. Mulay K, Ali MJ, Honavar SG, Reddy VA. Orbital alveolar soft-part sarcoma: clinicopathological profiles, management and outcomes. J Cancer Res Ther. 2014;10(2):294–298.
8. Altamirano-Dimas M, Albones-Saaavedra J. Alveolar soft part sarcoma of the orbit. Arch Ophthalmol. 1966;75(4):496–499.
9. Font RL, Jurco Jrd S, Zimmerman LE. Alveolar soft-part sarcoma of the orbit: a clinicopathologic analysis of seventeen cases and a review of the literature. Hum Pathol. 1982;13(6):569–579.
10. Rehki B, Ingle A, Agarwal ML, et al. Alveolar soft part sarcoma ‘revisited’: clinicopathological review of 47 cases from a tertiary cancer referral centre, including immunohistochemical expression of TFE3 in 22 cases and 21 other tumours. Pathology. 2012;44(1):11–17.
11. Kim HH, Wojno T, Grossniklaus HE, Shehata BM. Alveolar soft-part sarcoma of the orbit: report of 2 cases with review of the literature. Ophthalmic Plast Reconstr Surg. 2013;29(6):e138–142.
12. Xu X, Wu F, Hu H, et al. Pediatric alveolar soft part sarcoma of the orbit: a case report. J Biomed Res. 2014;30.
13. Mulay K, Chougule SS, Honavar SG. Orbital alveolar soft Part Sarcoma. Ophthalmol. 2016;123(7):1420.
14. Chaudhari PB, Pathe S, Deo SSV, et al. Alveolar soft part sarcoma of the orbit: a rare diagnosis. J Egypt Natl Canc Inst. 2017;29(3):167–170.
15. Kumar GK, Nemade H, Krishnamohan, et al. Rare case report of alveolar soft Part Sarcoma of the orbit. Indian J Surg Oncol. 2017;8(2):234–239.
16. Nava-Castaneda A, Tovilla-Canales JL, Zazo F, et al. Alveolar soft part sarcoma of the orbit, a case report of a rare tumor. Nepal J Ophthalmol. 2017;9(18):70–73.
17. de Barros GF, Hakim JR, Passos JP, et al. Orbital alveolar soft part sarcoma: case report and literature review. Can J Ophthalmol. 2019;54(6):e292–e294.
18. Al Ghailha FM, Kwon M, Sa HS. Alveolar soft part sarcoma of the lateral rectus muscle: suture technique to prevent postoperative strabismus. Am J Ophthalmol Case Rep. 2020, 18100666.
19. Majumder K, Saran R, Tyagi I, et al. Cyto diagnostics of alveolar soft part sarcoma: report of two cases with special emphasis on the first orbital lesion diagnosed by aspiration cytology. J Cytol. 2013;30(1):58–61.
20. Rose AM, Kabiru J, Rose GE. Alveolar soft-part sarcoma of the orbit. Afr J Paediatr Surg. 2011;8(1):82–84.
21. Alkatan H, Al-Shedoukhy AA, Chaudhry IA, Al-Ayoubi A. Orbital alveolar soft part sarcoma: Histopathologic report of two cases. Saudi J Ophthalmol. 2010;24(2):57–61.
22. Pang LJ, Chang B, Zou H, et al. Alveolar soft part sarcoma: a biomarker diagnostic strategy using TFE3 immunosanay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues. Diagn Mol Pathol. 2008;17(4):245–252.
23. Morris WR, Padgett DM, Osborn FD, Fleming JC. Pathologic quiz case: an orbital mass in a 45-year-old woman. *Arch Pathol Lab Med*. 2005;129(4):534–536.

24. Kanhere HA, Pai PS, Neeli SI, et al. Alveolar soft part sarcoma of the head and neck. *Int J Oral Maxillofac Surg*. 2005;34(4):268–272.

25. Kishiyap S, Sen S, Sharma MC, et al. Alveolar soft-part sarcoma of the orbit: report of three cases. *Can J Ophthalmol*. 2004;39(5):552–556.

26. Khan AO, Burke MJ. Alveolar soft-part sarcoma of the orbit. *J Pediatr Ophthalmol Strabismus*. 2004;41(4):245–246.

27. Chan WM, Liu DT, Lai CK, et al. Soft tissue sarcomas. Case 2. Orbital alveolar soft part sarcoma in a child. *J Clin Oncol*. 2004;22(10):2027–2029.

28. Lasudry J, Heimann P. Cytogenetic analysis of rare orbital tumors: further evidence for diagnostic implication. *Orbit*. 2000;19(2):87–95.

29. Coupland SE, Heimann H, Hoffmeister B, et al. Immunohistochemical examination of an orbital alveolar soft part sarcoma. *Graefes Arch Clin Exp Ophthalmol*. 1999;237(4):266–272.

30. Chodankar CM, Pandit SP, Joshi MG, Deodhar KP. Alveolar soft-part sarcoma of the orbit (a case report). *Indian J Ophthalmol*. 1986;34(1):67–68.

31. Ishikura A, Kimura A, Yamamoto S. A case of alveolar soft part sarcoma. *Jpn J Cancer Clin*. 1979, 25693.

32. Mukherjee PK, Agrawal S. Alveolar soft part sarcoma of the orbit. *Indian J Ophthalmol*. 1979;27(1):15–17.

33. Varghese S, Nair B, Joseph TA. Orbital malignant non-chromaffin paraganglioma. *Br J Ophthalmol*. 1968;52(9):713–715.

34. Abrahams IW, Fenton RH, Vidone R. Alveolar soft-part sarcoma of the orbit. *Arch Ophthalmol*. 1968;79(2):185–188.

35. Nirankari MS, Greer CH, Chaddah MR. Malignant non-chromaffin paraganglioma in the orbit. *Br J Ophthalmol*. 1963;47(6):357–363.

36. Sood S, Baheti AD, Shinagare AB, et al. Imaging features of primary and metastatic alveolar soft part sarcoma: single institute experience in 25 patients. *Br J Radiol*. 2014;87(1036), 20130715.

37. McCarville MB, Muzaffar S, Kao SC, et al. Imaging features of alveolar soft-part sarcoma: a report from Children’s Oncology Group Study ARST0332. *AJR Am J Roentgenol*. 2014;203(6):1345–1352.

38. Vire F, Orbach D, Klijnjenko J, et al. Alveolar soft part sarcoma-radiologic patterns in children and adolescents. *Pediatr Radiol*. 2013;43(9):1174–1181.

39. Chu WC, Howard RG, Roeback DJ, et al. Periorbital alveolar soft part sarcoma with radiologic features mimicking haemangioma. *Med Pediatr Oncol*. 2003;41(2):145–146.

40. Portera Jr CA, Ho V, Patel SR, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. *Cancer*. 2001;91(3):585–591.

41. Jordan DR, MacDonald H, Noel L, et al. Alveolar soft-part sarcoma of the orbit. *Ophthalmic Surg*. 1995;26(3):269–270.

42. Litircic O. Alveolar soft-part sarcoma. *Am J Ophthalmol*. 1982;94(4):554–556.

43. Bunt AH, Benninger RE. Alveolar soft-part sarcoma of the orbit. *Ophthalmology*. 1981;88(12):1339–1346.

44. Welsh RA, Bray 3rd DM, Shipley FH, Meyer AT. Histogenesis of alveolar soft part sarcoma. *Cancer*. 1972;29(1):191–204.

45. Grant GD, Shields JA, Flanagan JC, Horowitz P. The ultrasonographic and radiologic features of a histologically proven case of alveolar soft-part sarcoma of the orbit. *Am J Ophthalmol*. 1979;87(6):773–777.

46. Lieberman PH, Brennan MF, Kimmel M, et al. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. *Cancer*. 1989;63(1):1–13.

47. Sherman N, Vavilala M, Pollock R, et al. Radiation therapy for alveolar soft-part sarcoma. *Med Pediatr Oncol*. 1994;22(6):380–383.

48. Paoluzzi L, Maki R. Diagnosis, prognosis, and treatment of alveolar soft Part Sarcoma: a review. *JAMA Oncol*. 2019;5(2):254–260.